43
Anxiety Disorders Brian J. Piper, Ph.D.

Neuropharmacology: Anxiety Disorders

Embed Size (px)

DESCRIPTION

Lecture 21 from a college level neuropharmacology course taught in the spring 2012 semester by Brian J. Piper, Ph.D. ([email protected]) at Willamette University. Focus is on DSM IV TR criteria for anxiety disorders and their pharmacological treatments.

Citation preview

Page 1: Neuropharmacology: Anxiety Disorders

Anxiety Disorders

Brian J. Piper, Ph.D.

Page 2: Neuropharmacology: Anxiety Disorders

Primary Objectives

• Disorders– Generalized Anxiety Disorders– Panic Disorder– Phobias– Obsessive Compulsive Disorder– Post-Traumatic Stress Disorder

• Therapies– Barbiturates– Benzodiazepines– SSRIs– Others

• CBT• Psychosurgery

Page 3: Neuropharmacology: Anxiety Disorders

Secondary Objectives

• Neurochemistry– GABA– 5-HT

• Neuroanatomy– Amygdala– Anterior Cingulate Cortex– Basal Ganglia

• Methods– Open-field– Elevated Plus & Zero Mazes– Light-Dark Test– Conflict Test

Page 4: Neuropharmacology: Anxiety Disorders

Terminology• Fear (current) versus Anxiety (future)

4

Page 5: Neuropharmacology: Anxiety Disorders

Anxiety Disorders

Panic Disorder Phobias Generalized Anxiety Disorder Social Anxiety Disorder Obsessive-Compulsive Disorder Post-Traumatic Stress Disorder

Page 6: Neuropharmacology: Anxiety Disorders

Epidemiology

Kessler et al. (2005). Archives of General Psychiatry, 62, 617-627.

Page 7: Neuropharmacology: Anxiety Disorders

Panic Disorder

Panic Attack: discrete period of intense fear, 4+ symptoms develop abruptly and peak within 10 minutes

Individual Differences: multi/day versus 1/week

Agoraphobia: fear of open-spaces

1st 2:30http://www.youtube.com/watch?v=2gNGUartUEI

Page 8: Neuropharmacology: Anxiety Disorders

Phobia

• Marked & persistent fear that is excessive or unreasonable, cued by presence or anticipation of object/situation

• The avoidance interferes significantly with normal routine, occupational or social activities.

8

Page 9: Neuropharmacology: Anxiety Disorders

Kinds of Phobias

Phobia of blood.Hemophobia

Phobia of closed spaces.

Claustrophobia

Phobia of heights.Acrophobia

Phobia of spiders.Arachonophobia

Page 10: Neuropharmacology: Anxiety Disorders

Systematic Desensitization

• 1) Create hierarchy of fears• 2) Relaxation techniques• 3) Combine

Spider

Joseph Wolpe, M.D.

1915-1997

Page 11: Neuropharmacology: Anxiety Disorders

Obsessive-Compulsive Disorder

• Obsessions– 1. Recurrent and persistent thoughts, urges, or

images that are experienced, at some time during the disturbance, as intrusive and unwanted and that in most individuals cause marked anxiety or distress

– 2. The person attempts to ignore or suppress such thoughts, urges, or images, or to neutralize them with some other thought or action (i.e., by performing a compulsion)

Page 12: Neuropharmacology: Anxiety Disorders

Compulsions

• 1. Repetitive behaviors (e.g., hand washing, ordering, checking) or mental acts (e.g., praying, counting, repeating words silently) that the person feels driven to perform in response to an obsession, or according to rules that must be applied rigidly

• 2. The behaviors or mental acts are aimed at preventing or reducing anxiety or distress, or preventing some dreaded event or situation; however, these behaviors or mental acts either are not connected in a realistic way with what they are designed to neutralize or prevent, or are clearly excessive

Page 13: Neuropharmacology: Anxiety Disorders

OCD

• 1st Two Minutes:• http://www.youtube.com/watch?v=44DCWslb

sNM

13

Page 14: Neuropharmacology: Anxiety Disorders

Cingulate Cortex

14

Page 15: Neuropharmacology: Anxiety Disorders

Anterior Cingulate & OCD

• OCD and controls completed a difficult continuous performance test during fMRI.

• OCD > controls in Anterior Cingulate Cortex

• Target of psychosurgery

15Ursu et al. (2003). Psychological Science, 14, 347-353.

Page 16: Neuropharmacology: Anxiety Disorders

Psychosurgery

• 1949: Antonio Egas Moniz received Nobel prize for frontal leucotomy

• 1940s-1967: Walter Freeman develops frontal lobotomy (transorbital)

• Current: lesioning & deep brain stimulation is a last resort

1874-1955

Page 17: Neuropharmacology: Anxiety Disorders

Generalized Anxiety Disorder

A. Excessive anxiety and worry (apprehensive expectation), occurring more-days-than-not for at least 6 months.

B. The person finds it difficult to control the worry.

C. three (or more) of the following six symptoms:1. Restlessness2. Being easily fatigued3. Difficulty concentrating4. Irritability5. Muscle tension6. Sleep disturbance

DSM-IV-TR Criteria

Page 18: Neuropharmacology: Anxiety Disorders

Post-Traumatic Stress Disorder

Four or more weeks of the following symptoms constitute Post-Traumatic Stress Disorder (PTSD):

Re-experiencing: nightmares, flashbacks, intrusive thoughts

Avoidance: situation & associated

Physical Arousal: sleep, concentration, irritability

Significant social or occupational impairment3 min: http://www.youtube.com/watch?v=7aFs6695VyQ

Lifetime Prevalence: 5% men, 10% women

Page 19: Neuropharmacology: Anxiety Disorders

PTSD Talk Therapy• Participant groups matched based on prior trauma

(moderate), sex, and age• Eye Movement Desensitization & Reprocessing: imagine trauma + follow therapists

rapidly moving finger• Control: imagine trauma while staring at stationary object (same duration as

experimental

**

Dunn et al. (1996). J Behav Therapy Exp Psychiatry, 27, 231-239.

Page 20: Neuropharmacology: Anxiety Disorders

Barbiturates

• Barbital synthesized in 1903• Popular sleep aid until 1950s• Act on GABAA in limbic system

http://images.google.com/imgres?imgurl=http://pubs.acs.org/cen/img/83/i25/8325pheno_barbara.tifcxd.JPG&imgrefurl=http://pubs.acs.org/cen/coverstory/83/8325/8325phenobarbital.html&h=287&w=156&sz=46&hl=en&sig2=zuAuHA0TzlNEk45oUL1xHw&start=19&tbnid=heE_tNcgW041OM:&tbnh=115&tbnw=63&ei=bRW0RI6zEMaoaK-a5bAG&prev=/images%3Fq%3Dphenobarbital%26svnum%3D10%26hl%3Den%26lr%3D%26rls%3DCNDB,CNDB:2004-15,CNDB:en

Page 21: Neuropharmacology: Anxiety Disorders

Comparison

(Long)

(Ultrashort)

(Short)(Long)

Page 22: Neuropharmacology: Anxiety Disorders

Valium

• Invented by Leo Sternbach and began use in 1963

• Uses: anxiety, insomnia, cocaine OD• PK: long half life, bioactive metabolites• PD: Bezodiazepine site on GABAA

1908-2005

Page 23: Neuropharmacology: Anxiety Disorders

Animal Models of Anxiety: Elevated Zero Maze

• Dependent Variable: % Open

Braun et al. (2011). Pharmacol Biochem Behav, 97, 406-415.

Page 24: Neuropharmacology: Anxiety Disorders

Benzodiazepine Tolerance

• Mice received implants to deliver 2 mg/kg/day of lorazepam.

• Three behaviors were measured in an open field.

Fahey et al. (2001). Pharmacology Biochemistry Behavior 69, 1-8.

Page 25: Neuropharmacology: Anxiety Disorders

Cross Tolerance• The benzodiazepine chlordiazepoxide (CDP) or

diazepam (DZ) impaired tilt-plane performance.

• Ethanol caused a greater disruption in benzo naïve rats.

Khana et al. (1998) Pharm Biochem Behav 59, 511-519.

Page 27: Neuropharmacology: Anxiety Disorders

Self-administration

Opiates > Benzodiazepines > Hallucinogens

Page 28: Neuropharmacology: Anxiety Disorders

GABA Receptors

• Receptor is composed of 5 subunits.

• Binding of GABA results in influx of Chloride.

• Other drugs also bind to receptor.

• GABAA & GABAB

Page 29: Neuropharmacology: Anxiety Disorders

GABAA

Barbiturates: open channel

Benzodiazepines open channel only if GABA

present

Page 30: Neuropharmacology: Anxiety Disorders

Light Dark Test

• Dependent Measure: % time in lit area• Anxiolytic: increased % time in lit area• Anxiogenic: decreased % time in lit area

Page 31: Neuropharmacology: Anxiety Disorders

Light Dark Test

• Role of GABA or 5-HT in anxiety

--------------------------------- --------------------------------------------------

Page 32: Neuropharmacology: Anxiety Disorders

Vogel Conflict Test

• Water deprived animals will get mild footshock for drinking H2O

Basso et al. (2011). Behavioral Brain Research, 218, 174-183.

Page 33: Neuropharmacology: Anxiety Disorders

Gamma-hydroxybutyrate

• Georgia Home Boy, Grevious Bodily Harm, Liquid X

• Clear and salty liquid, rave & date rape drug• Medical uses: Narcolepsy (cataplexy) and anesthetic• PK: half-life of 40 min • PD: GABAB & GHB agonist

GABA GHB

Page 34: Neuropharmacology: Anxiety Disorders

Forensic Applications

Kintz (2005) J Forensic Sci 28(1), 1-6.

Page 35: Neuropharmacology: Anxiety Disorders

Forensic Applications

Kintz (2005) J Forensic Sci 28(1), 1-6.

Page 36: Neuropharmacology: Anxiety Disorders

GHB and Behavior

• Flies received GHB by injection (!).

• GHB increased immobility in normal (wild-type) and EtOH sensitive (Cheapdate) flies.

• A GABAB antagonist prevented these effects.

Dimitrijevic et al. (2005). European J Pharmacol, 519, 246-252.

Page 37: Neuropharmacology: Anxiety Disorders

Utility of Multimodal

• Children (ages 7-12, N=488) with one (GAD, separation anxiety disorder, social phobia: 21.9%), or more anxiety disorders (78.1%) were randomized to placebo, Cognitive Behavioral Therapy, sertraline, or sertraline/CBT for 12 weeks.

Walkup et al. (2005) NEJM, 359, 2753-2766.

Page 38: Neuropharmacology: Anxiety Disorders

Utility of Multimodal

ImprovementPlacebo: 7.0CBT: 8.1Sertraline: 9.0Combo: 12.0

Page 39: Neuropharmacology: Anxiety Disorders

But Differential Side-Effects Rates

Zoloft - Zoloft +0

5

10

15

20

25 *

Page 40: Neuropharmacology: Anxiety Disorders

Videocast

• Charney, Dennis S. (2002). Underlieing mechanisms of Anxiety & Post-Traumatic Stress. Starts at 04:00 to 36:00 http://videocast.nih.gov/launch.asp?10696

Page 41: Neuropharmacology: Anxiety Disorders

Summary

http://www.nimh.nih.gov/statistics/index.shtml

Disorder Adult Lifetime %

AdolescentLifetime %

1st Line Tx 2nd Line Tx

GAD 5.7 1.0 CBT, SSRI, SSNRI Benzos

Panic Disorder 4.7 2.3 CBT, SSRI

Phobias 12.5 15.1 Systematic Desensitization

OCD 1.6 - CBT, SSRI Benzospsychosurgery

PTSD 6.8 4.0 CBT, SSRI EMDR

Page 42: Neuropharmacology: Anxiety Disorders

Origins of Anxiety

• Learn: videotapes of fear response to fake snake or plastic flower

• Test: show a stimuli

Mineka, S. (1985). J Abnormal Psychol

Page 43: Neuropharmacology: Anxiety Disorders

Origins of Anxiety(Susan Mineka)

• Learn: videotapes of fear response to fake snake or plastic flower

• Test: show a stimuli• Response: Snake-Fear; Flower- No Fear• Supports Social-Learning & Evolutionary

Psychology